FATLAS: Comprehensive Multi-level Characterization of Systemic and Mammary Adiposity in Breast Cancer Patients. (FATLAS)

• ClinicalTrials.gov Identifier: NCT04200768
• Recruitment Status: Recruiting
• First Posted: December 16, 2019
• Last Update Posted: January 27, 2023
• Sponsor: Universitaire Ziekenhuizen KU Leuven
• Collaborator: KU Leuven
• Information provided by (Responsible Party): Universitaire Ziekenhuizen KU Leuven

Study Description

Brief Summary:

FATLAS is a prospective, interventional, non Investigational Medicinal Product (IMP) study aiming to characterize the micro- and macroenvironment of breast cancer according to patient adiposity in different histological and molecular subtypes.

The macroscopic profiling of the patient's adiposity will be based on Body Mass Index (BMI), bioimpedance analysis and waist-to-hip ratio. Blood samples will be taken for lipidomic analyses and for hormonal and immuno assays. Microscopic profiling of adiposity and inflammation will be done on fresh frozen (FF) and Formalin-Fixed Paraffin-Embedded (FFPE) samples from the tumour resection specimen and will consist of histological characterization, immuno assays, multiplex immunohistochemistry, DNA sequencing and single nuclei RNA sequencing both in the tumour and in adjacent normal mammary tissue.

Condition or disease	Intervention/treatment	Phase
Breast Neoplasms	Other: Prospective data and sample collection	Not Applicable

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 150 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Basic Science
• Official Title: FATLAS: Comprehensive Multi-level Characterization of Systemic and Mammary Adiposity in Breast Cancer Patients.
• Actual Study Start Date: September 1, 2020
• Estimated Primary Completion Date: October 31, 2024
• Estimated Study Completion Date: October 31, 2024

Arms and Interventions

Arm	Intervention/treatment
Standard; Standard of care	Other: Prospective data and sample collection; Performance of measurements of adiposity, extra collection of blood samples

Outcome Measures

Primary Outcome Measures :

1. BMI [ Time Frame: Before surgery ]
   Calculated: body mass (kg) divided by height squared (m²)
2. Lipid levels in plasma [ Time Frame: Before surgery ]
   Lipidomic analysis
3. Up- or downregulation of pathways on single cell level [ Time Frame: At surgery ]
   Single nucleus RNA sequencing using 10X Genomics Platform after dissociation of tissue into single nuclei
4. T cell repertoire [ Time Frame: At surgery ]
   Number of T-cells per population using immunohistochemical phenotypic markers of cell type and of exhaustion.
5. Physical activity level [ Time Frame: Before surgery ]
   Time of activity of different intensities and time of sedentarity, evaluated using the Global Physical Activity Questionnaire (GPAQ) of the World Health Organisation (WHO) (scale: minutes per day, range [0 - 1440]). The higher the score for activity the better, the lower the score for sedentarity the better.
6. Sleep behaviour score [ Time Frame: Before surgery ]
   Pittsburgh Sleep Quality Index (PSQI) score (range: [0 - 21]). Higher scores indicate worse sleep quality.
7. Dietary Quality Index [ Time Frame: Before surgery ]
   Nutritional score (natural number, range [0 - 100]) calculated using the in-house Food Frequency Questionnaire. A score of > 70 indicates healthy dietary behaviour.
8. Dietary Food Intake [ Time Frame: Before surgery ]
   Food intake in kcal per day calculated using the in-house Food Frequency Questionnaire.
9. Fat percentage [ Time Frame: Before surgery ]
   Calculated from multiple frequency bio-impedance measurements (in %, range [0 - 100]).
10. Waist-to-hip ratio [ Time Frame: Before surgery ]
    Waist circumference (cm) divided by hip circumference (cm)
11. Handgrip strength [ Time Frame: Before surgery ]
    In kilograms (kg), measured by handheld dynamometer.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 75 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

Inclusion of 30 lean (BMI 18.5 - 24.9 kg/m²), 30 overweight (BMI 25 - 29.9 kg/m²), and 30 obese (BMI ≥ 30 kg/m²) patients with histological confirmation of Invasive Ductal Carcinoma (IDC) on core diagnostic biopsy; 5 lean, 5 overweight and 5 obese Inflammatory Breast Cancer (IBC) patients; 15 lean, 15 overweight and 15 obese patients with histological confirmation of Invasive Lobular Carcinoma (ILC) on core diagnostic biopsy and 20 male subjects with any type of breast cancer that meet following criteria:

• be willing and able to provide written informed consent for this study;
• be willing to provide plasma/blood and tissue samples;
• be willing to have clinical measures of adiposity taken;
• have stage I, II or III disease (so non-metastatic) with any clinical lymph node status;
• be scheduled for surgical resection of the tumour in UZ Leuven.
• have a tumour size of ≥ 1.5 cm in order to have sufficient tumour material for the biomarker analysis. Exceptions will be made for IBC patients, as in some cases no residual tumour will be found after neoadjuvant treatment;
• be treatment naïve, i.e. not having received systemic breast cancer treatment prior to surgery. An exception is made for the IBC patients, as they will often have received first line neoadjuvant chemotherapy before surgery. IBC patients that do not undergo surgery after neoadjuvant treatment (e.g. because of inoperability of the patient) will not be included;

Exclusion Criteria:

• pregnancy at time of diagnosis;
• personal history of breast cancer (relapse/second primary);
• mixed invasive tumour type on core biopsy or special type of breast carcinoma beside pure ILC;
• history of an additional malignancy that is progressing or that has required active treatment in the 5 years prior to breast cancer diagnosis. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that have undergone potentially curative therapy or in situ cervical cancer;
• presence of an immune dysregulatory disease or condition which requires active immune modulatory treatment of any kind, or has required treatment in the past two years. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment;
• history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial in the opinion of the treating investigator.

Contacts and Locations

Contacts

Contact: Marion Maetens, PhD; +3216321194; marion.maetens@kuleuven.be

Locations

Belgium

UZ Leuven; Recruiting

Leuven, Belgium, 3000

Contact: Marion Maetens, PhD +3216321194 marion.maetens@kuleuven.be

Contact: Tatjana Geukens, MD +3216321194 tatjana.geukens@kuleuven.be

Sub-Investigator: Christine Desmedt, PhD

Principal Investigator: Giuseppe Floris, MD PhD

Sponsors and Collaborators

Universitaire Ziekenhuizen KU Leuven

KU Leuven

More Information

• Responsible Party: Universitaire Ziekenhuizen KU Leuven
• ClinicalTrials.gov Identifier: NCT04200768
• Other Study ID Numbers: S63330
• First Posted: December 16, 2019
• Last Update Posted: January 27, 2023
• Last Verified: November 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Universitaire Ziekenhuizen KU Leuven:

Breast Cancer; Body Mass Index; Adiposity; Obesity; Inflammatory Breast Cancer; Lobular Breast Cancer; Tumour Microenvironment

Additional relevant MeSH terms:

Breast Neoplasms; Obesity; Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Overweight; Overnutrition; Nutrition Disorders; Body Weight